References
- Rutkowski P, Warzocha K. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych, Mięsaki kości, 2013 rok. VM Media Sp z o.o., ISBN 9788375995947.
- Marais L, Bertie J, Rodseth R, Sartorius B, Ferreira N. Pre-treatment serum lactate dehydrogenase and alkaline phosphatase as predictors of metastases in extremity osteosarcoma 2015;4(3):80-84.
- Gajewska N, Ambroszkiewicz J, Rychlowska-Pruszynska M, Laskowska-Klita T. Markers of bone formation in children with osteosarcoma. Med. Wieku Rozwoj. 2004;8:235-243.
- Ługowska I, Woźniak W, Ambroszkiewicz J, et al. Extracellular domain of HER-2 as a prognostic factor in osteosarcoma. A pilot study. Med. Wieku Rozwoj. 2009;13:201-208.
- Limmahakhun S, Pothacharoen P, Theera-Umpon N, et al. Relationships between serum biomarker levels and clinical presentation of human osteosarcomas. Asian Pac J Cancer Prev. 2011;12:1717-1722.
- Sternberg RA, Pondenis HC, Yang X, et al. Association between absolute tumor burden and serum bone-specific alkaline phosphatase in canine appendicular osteosarcoma. J Vet Intern Med. 2013;27:955-963.
- Mohamed A, Krajewski K, Cakar B. Targeted therapy for breast cancer, 2013;183(4):1096-1112.
- Laudadio J, Quigley D I, Tubbs R., Wolff D J. HER2 testing: a review of detection methodologies and their clinical performance. Expert Rev Mol Diagn. 2007;7(1):53-64.
- Esserman LJ, Moore DH, Tsing P J, et al. Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat. 2011;129(2):607-616.
- Holzer G, Pfandlsteiner T, Koschat M, Noske H, Trieb K, Kotz R. Soluble p185HER-2 in Patients With Malignant Bone Tumours. Pediatric Blood Cancer 2005;44:163-166.
- Ambroszkiewicz J, Gajewska J, Klepacka T, Chełchowska M, Laskowska-Klita T, Woźniak W. A comparison of serum concentrations of biochemical bone turnover markers in patients with osteosarcoma with good and poor prognosis. Polski Merkurisz Lekarski, 2010;29(169):19-26.
- Liu PP, Leung KS, Kumta SM et al. Bone-specific alkaline phosphatase in plasma as tumour marker for osteosarcoma. Oncology, 1996;53(4):275-280.
- Zhiping Y, Yanqing H, Guangzhi S et al. Measurement of bone alkaline phosphatase and relative study with osteosarcoma. Front. Med. China, 2007;1(1):54-57.
- Levine AM, Triche T, Rosenberg SA. Osteosarcoma cells in tissue culture: Characterisation and localization of alkaline phosphatase activity. Clin. Orthop. Rel. Res., 1980;146:259-268.
- Lim SM, Kim Y N, Park K H, Kang B, Chon H J, Kim C, Kim J H, Rha S Y. Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. BMC Cancer. 2016;16:385.
- Wasilewski-Masker K, Kastle SC, Hudson M M. et al. Bone mineral density deficits in survivors of childhood cancer: Long-term follow-up guidelines and review of the literature. Pediatrics, 2008;121(3):705-713.
- Dresner-Pollak R, Parker R A, Poku M, Thompson J, Seibel M J, Greenspan S L. Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int. 1996;59(5):328-333.
- Rauchenzauner M, Schmid A, Heinz-Erian P, Kapelari K, Falkensammer G, Griesmacher A, Finkenstedt G, Högler W. Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab. 2007;92(2):443-449.
- Bargmann C I, Hung MC, Weinberg R A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319(6050):226-230.
- Gill J, Gellel D, Gorlick R. HER-2 Involvement in Osteosarcoma. Advances in Experimental Medicine and Biology 2014;804:161-181.